This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Marc C. Chamberlain, MD; Patty A. Kormanik, RN, MS

Arch Neurol. 1997;54(11):1364-1368.

Abstract
Objective
To assess the clinical significance of bulky metastatic central nervous system disease in patients with leptomeningeal metastases.

Patients and Methods
Forty patients (24 women and 16 men) ranging in age from 32 to 74 years (median, 56.5 years) with cytologically documented leptomeningeal metastases were demonstrated by cranial or spinal magnetic resonance imaging to have either no bulky central nervous system metastatic disease (group A; 20 patients) or bulky central nervous system metastatic disease (group B; 20 patients). Twenty-nine patients were treated with involved-field radiotherapy, and all patients were treated with sequential intraventricular chemotherapy.

Results
Median survival was 7 months in group A (range, 5-12 months) as compared with 4 months in group B (range, 2-12 months) (P<.01; Mantel-Cox log rank analysis). Cause of death was similar in both patient groups.

Conclusions
In patients with leptomeningeal metastases, neuroradiographic demonstration of bulky metastatic central nervous system disease independently predicts survival and is useful in determining which patients are candidates for intraventricular chemotherapy.

Author Affiliations
From the University of California, San Diego. Dr Chamberlain is now affiliated with Kaiser Permanente Southern California, Baldwin Park.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neoplastic Meningitis-Related Prognostic Significance of the Karnofsky Performance Status
Chamberlain et al.
Arch Neurol 2009;66:74-78.
ABSTRACT | FULL TEXT  

Neoplastic Meningitis
Chamberlain
The Oncologist 2008;13:967-977.
ABSTRACT | FULL TEXT  

Prognostic factors and outcomes in patients with leptomeningeal melanomatosis
Harstad et al.
Neuro Oncol Duke 2008;10:1010-1018.
ABSTRACT | FULL TEXT  

Intra-CSF Rituximab for Lymhomatous Meningitis
Chamberlain and Glantz
JCO 2007;25:4508-4509.
FULL TEXT  

Mafosfamide: A New Intra-CSF Chemotherapy?
Chamberlain
JCO 2005;23:7748-7749.
FULL TEXT  

Neoplastic Meningitis
Chamberlain
JCO 2005;23:3605-3613.
ABSTRACT | FULL TEXT  

Commentary Regarding Neoplastic Meningitis Secondary to Multiple Myeloma
Chamberlain
Arch Neurol 2005;62:833-833.
FULL TEXT  

A comparison between ventricular and lumbar cerebrospinal `uid cytology in adult patients with leptomeningeal metastases
Chamberlain et al.
Neuro Oncol Duke 2001;3:42-45.
ABSTRACT  

A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors
Glantz et al.
Clin. Cancer Res. 1999;5:3394-3402.
ABSTRACT | FULL TEXT  

111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases
Chamberlain et al.
Neurology 1999;52:214-214.
FULL TEXT